Noguchi P, et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-408, 1979. PubMed: 90012
Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111
Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642
Smith SG, et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. 53: 5697-5706, 1993. PubMed: 8242626
Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228
Petricciani JC, et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res. 34: 105-108, 1974. PubMed: 4203458
Tsuboi KK, Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res. 38: 3745-3750, 1978. PubMed: 698934
Noguchi PD, et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. PubMed: 203036
Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066
Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963
Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells
|